News
SPHDF
22.85
NaN%
--
Weekly Report: what happened at SPHDF last week (0427-0501)?
Weekly Report · 1d ago
Analyst Reiterates Buy on Santhera, Citing Leadership Transition and AGAMREE Momentum with Unchanged $30 Price Target
TipRanks · 04/27 10:26
Weekly Report: what happened at SPHDF last week (0420-0424)?
Weekly Report · 04/27 10:21
Santhera Receives Positive CHMP Opinion In Age Range Expansion For AGAMREE In Treating DMD
NASDAQ · 04/27 09:30
Santhera Moves Closer To Earlier Treatment Access For Young DMD Patients In Europe
NASDAQ · 04/27 08:11
Weekly Report: what happened at SPHDF last week (0413-0417)?
Weekly Report · 04/20 10:17
Weekly Report: what happened at SPHDF last week (0406-0410)?
Weekly Report · 04/13 10:21
Santhera: Advancing AGAMREE Reimbursement and European Uptake Underpins Reiterated Buy and CHF30 Target
TipRanks · 04/08 10:16
Weekly Report: what happened at SPHDF last week (0330-0403)?
Weekly Report · 04/06 10:22
Weekly Report: what happened at SPHDF last week (0323-0327)?
Weekly Report · 03/30 10:22
Weekly Report: what happened at SPHDF last week (0316-0320)?
Weekly Report · 03/23 10:18
Weekly Report: what happened at SPHDF last week (0309-0313)?
Weekly Report · 03/16 10:17
Santhera Pharma Appoints Marc Clausse As Chief Commercial Officer
NASDAQ · 03/10 06:09
Weekly Report: what happened at SPHDF last week (0302-0306)?
Weekly Report · 03/09 10:18
Weekly Report: what happened at SPHDF last week (0223-0227)?
Weekly Report · 03/02 10:17
Weekly Report: what happened at SPHDF last week (0216-0220)?
Weekly Report · 02/23 10:17
Weekly Report: what happened at SPHDF last week (0209-0213)?
Weekly Report · 02/16 10:17
Weekly Report: what happened at SPHDF last week (0202-0206)?
Weekly Report · 02/09 10:18
Weekly Report: what happened at SPHDF last week (0126-0130)?
Weekly Report · 02/02 10:18
Weekly Report: what happened at SPHDF last week (0119-0123)?
Weekly Report · 01/26 10:18
More
Webull provides a variety of real-time SPHDF stock news. You can receive the latest news about Santhera Pharmaceuticals Hldgs through multiple platforms. This information may help you make smarter investment decisions.
About SPHDF
Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company operates through one business segment, which is the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases, such as Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF). The Company focuses also on development of gene therapy for the treatment of LAMA2 (Laminin Subunit Alpha 2) deficient congenital muscular dystrophy (CMD). Santhera operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.